B

BioPharma Dive

http://www.biopharmadive.com/feeds/news/ (RSS订阅地址)

Kura spins diabetes work into a Lilly-backed biotech startup

<figure><div><img src="https://imgproxy.citrusreader.com/ZvZW3M0ARY_aEgQ-s5Mu-aa5EAjWGqhY48EMCwLlehI/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS9KU0w2TUZ4XzdHODJma2R0MmI1eGFEMUZxeTNfemRVX0Y3Qy1qMFRKaXk4L2c6bm93ZTo4ODo5NzUvYzo1MjU5OjI5NzEvcnM6ZmlsbDoxNjAwOjkwMDoxL1ozTTZMeTlrYVhabGMybDBaUzF6ZEc5eVlXZGxMMlJwZG1WcGJXRm5aUzlIWlhSMGVVbHRZV2RsY3kweE5UYzRPREUyTlRRM0xtcHdadz09LndlYnA"></div></figure><p>Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.</p>

2026/9/9
阅读更多

FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders

<figure><div><img src="https://imgproxy.citrusreader.com/2pb_vNPXUhBlhHOnsludJBvYf0IRR5sgLvn-6Pb1UUg/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS9mNWE0VlJEWFFnLVN3SDJ5QkRLSGJ0TGV5VkhwWDhjZW1uU2JlLXQtNnhVL2c6Y2UvcnM6ZmlsbDoxNjAwOjkwMDoxL1ozTTZMeTlrYVhabGMybDBaUzF6ZEc5eVlXZGxMMlJwZG1WcGJXRm5aUzlIWlhSMGVVbHRZV2RsY3kweE1qSTNOekV3TkRrNFgwRjVRa3R6VmswdWFuQm4ud2VicA"></div></figure><p>After almost two years of turnover in the FDA&rsquo;s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.&nbsp;</p>

2026/9/9
阅读更多

A new immuno-oncology play raises $225M for a next-generation drug

<figure><div><img src="https://imgproxy.citrusreader.com/nguNYXfDWYIG5sK_Coz8SNJVIbxOFFtwMxNkPZfAvDE/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS90MmVTUUZuVUxUUlBRNnBIb0Y3NGlsUlRkckFsRXZ2RlJPc0lUc2loQWx3L2c6Y2UvcnM6ZmlsbDoxNjAwOjkwMDoxL1ozTTZMeTlrYVhabGMybDBaUzF6ZEc5eVlXZGxMMlJwZG1WcGJXRm5aUzlIWlhSMGVVbHRZV2RsY3kweU1EVXpNRFExTlRjekxtcHdadz09LndlYnA"></div></figure><p>Solstice Oncology is advancing a medicine from China&rsquo;s Harbour BioMed that it believes is able to address the weaknesses of drugs&nbsp;aimed at CTLA-4, a popular but tricky cancer immunotherapy target.</p>

2026/9/9
阅读更多

Six AI agents, one deskside system: A new model for clinical decision support

<p>Multi-agent AI reasoning at the point of care, with complete data sovereignty built in.</p>

2026/9/8
阅读更多

Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

<figure><div><img src="https://imgproxy.citrusreader.com/iepLHbsQz3mmP1iutD41a9Thi4-j5PQrJwqZi7fpqX8/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS9pZHNkTUFIc1BiWE9iRFV0UVcycVJHN3V2ZUJVVnY2SENUbjlOVHRsRE9JL2c6bm93ZTowOjAvYzoxMjA3OjY4Mi9yczpmaWxsOjE2MDA6OTAwOjEvWjNNNkx5OWthWFpsYzJsMFpTMXpkRzl5WVdkbEwyUnBkbVZwYldGblpTOUhaWFIwZVVsdFlXZGxjeTB4TkRnek9USXhOemt6TG1wd1p3PT0ud2VicA"></div></figure><p>One analyst views Roivant&rsquo;s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere,&nbsp;AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.</p>

2026/9/8
阅读更多

Moonwalk reloads with $70M and new RNAi prospects for obesity

<p>The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.</p>

2026/9/8
阅读更多

Novartis RNA drug falls short in rare muscle disease study

<p>The failure of &ldquo;del-desiran,&rdquo; which Novartis got through a $12 billion acquisition, could raise questions about the company&rsquo;s business development acumen, according to one analyst.</p>

2026/9/8
阅读更多

BrainChild hauls in $116M to make cell therapies for childhood brain cancers

<figure><div><img src="https://imgproxy.citrusreader.com/BCvvlse380K_hiJBUggMOv58aYlZl-vFyzgMLjJYyS8/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS84UzF3SUdGcEZXYWRuYnVqT2R1YUNKRFBqQnlQRVZvSDR5c1FqY21fRjFrL2c6Y2UvcnM6ZmlsbDoxNjAwOjkwMDoxL1ozTTZMeTlrYVhabGMybDBaUzF6ZEc5eVlXZGxMMlJwZG1WcGJXRm5aUzl6WldGMGRHeGxMV05vYVd4a2NtVnVjeTFvYjNOd2FYUmhiQzFqWVcxd2RYTXRaWGgwWlhKcGIzSXROUzV3Ym1jPS53ZWJw"></div></figure><p>Spun out of research at Seattle Children&rsquo;s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.</p>

2026/9/8
阅读更多

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

<figure><div><img src="https://imgproxy.citrusreader.com/LZZNJFD2W9_usmehthl1dXGHU1pr4T1F5zkMraH2VSc/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS9hcVcwT2x1R3hlVGpnUU1DMzFzS0Q2ci15bzJvanJIZ0ZnU1BsX3BxenVZL2c6bm93ZTowOjEyNjMvYzo1NjE2OjMxNzMvcnM6ZmlsbDoxNjAwOjkwMDoxL1ozTTZMeTlrYVhabGMybDBaUzF6ZEc5eVlXZGxMMlJwZG1WcGJXRm5aUzlIWlhSMGVVbHRZV2RsY3kweE1UTXhOVEV3T1RBNExtcHdadz09LndlYnA"></div></figure><p>Pelacarsen didn&rsquo;t protect heart health despite lowering levels of a protein particle, &ldquo;Lp(a),&rdquo; in a large clinical trial &mdash; a surprise result with important implications for cardiovascular drug research.</p>

2026/9/5
阅读更多

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

<figure><div><img src="https://imgproxy.citrusreader.com/0hmTHhXOmEYffq4GWZ5jiLRdLHZzSixOUVdLgTcKAUc/raw:1/aHR0cHM6Ly9pbWdwcm94eS5kaXZlY2RuLmNvbS8wY25md2U1ZDQzR2hKbUtldGRtYUs4cUlFdFVGSC1PemJ6R1BYRXUxNjNNL2c6Y2UvcnM6ZmlsbDoxNjAwOjkwMDoxL1ozTTZMeTlrYVhabGMybDBaUzF6ZEc5eVlXZGxMMlJwZG1WcGJXRm5aUzh5UjBKTE4wSlpMbXB3Wnc9PS53ZWJw"></div></figure><p>The drugmaker is leaning on a better side effect profile compared to drugs from J&amp;J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.</p>

2026/9/4
阅读更多

推荐订阅

Breaking World Pharma News

FierceBiotech

Nomadic Matt's Travel Site

View from the Wing

One Mile at a Time